
Galera Therapeutics Stock
Therapeutic agents for preventing damage due to radiation treatment of cancer
Sign up today and learn more about Galera Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Galera Therapeutics Stock
Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, its lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.
Funding History
January 2011 | $805K |
---|---|
September 2011 | $405K |
December 2012 | $11.0M |
August 2014 | $4.7M |
March 2015 | $4.7M |
October 2015 | $37.0M |
February 2016 | $5.0M |
November 2016 | $15.0M |
September 2018 | $70.0M |
Management
President, Chief Executive Officer & Board of Directors
Mel Sorensen
Co-Founder & Chief Scientific Officer
Dennis P. Riley
Chief Medical Officer
Jon T. Holmlund
Executive Chair, Board of Directors
Robert Alan Beardsley
Founder, Executive Chair, Board of Directors
Robert Beardsley
CFO
Joel Sussman
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase